ID   MCE_VACCW               Reviewed;         333 AA.
AC   P07617;
DT   01-APR-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1988, sequence version 1.
DT   01-APR-2015, entry version 106.
DE   RecName: Full=Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase;
DE            EC=2.1.1.57;
DE   AltName: Full=Poly(A) polymerase regulatory subunit;
DE   AltName: Full=Poly(A) polymerase small subunit;
DE            Short=PAP-S;
DE   AltName: Full=VP39;
GN   Name=PAPS; OrderedLocusNames=VACWR095; ORFNames=J3R;
OS   Vaccinia virus (strain Western Reserve) (VACV) (Vaccinia virus (strain
OS   WR)).
OC   Viruses; dsDNA viruses, no RNA stage; Poxviridae; Chordopoxvirinae;
OC   Orthopoxvirus; Vaccinia virus.
OX   NCBI_TaxID=10254;
OH   NCBI_TaxID=9913; Bos taurus (Bovine).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2987815; DOI=10.1093/nar/13.3.985;
RA   Plucienniczak A., Schroeder E., Zettlmeissl G., Streeck R.E.;
RT   "Nucleotide sequence of a cluster of early and late genes in a
RT   conserved segment of the vaccinia virus genome.";
RL   Nucleic Acids Res. 13:985-998(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Esposito J.J., Frace A.M., Sammons S.A., Olsen-Rasmussen M.,
RA   Osborne J., Wohlhueter R.;
RT   "Sequencing of the coding region of Vaccinia-WR to an average 9-fold
RT   redundancy and an error rate of 0.16/10kb.";
RL   Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   PROTEIN SEQUENCE OF 196-205; 210-219 AND 247-256, AND FUNCTION.
RX   PubMed=1313572; DOI=10.1073/pnas.89.7.2897;
RA   Schnierle B.S., Gershon P.D., Moss B.;
RT   "Cap-specific mRNA (nucleoside-O2'-)-methyltransferase and poly(A)
RT   polymerase stimulatory activities of vaccinia virus are mediated by a
RT   single protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:2897-2901(1992).
RN   [4]
RP   FUNCTION, AND INTERACTION WITH VP55/E1.
RX   PubMed=1670500; DOI=10.1016/0092-8674(91)90048-4;
RA   Gershon P.D., Ahn B.-Y., Garfield M., Moss B.;
RT   "Poly(A) polymerase and a dissociable polyadenylation stimulatory
RT   factor encoded by vaccinia virus.";
RL   Cell 66:1269-1278(1991).
RN   [5]
RP   INTERACTION WITH H4 AND NPH-I/D11.
RX   PubMed=11162828; DOI=10.1006/viro.2000.0749;
RA   Mohamed M.R., Latner D.R., Condit R.C., Niles E.G.;
RT   "Interaction between the J3R subunit of vaccinia virus poly(A)
RT   polymerase and the H4L subunit of the viral RNA polymerase.";
RL   Virology 280:143-152(2001).
RN   [6]
RP   RNA-BINDING.
RX   PubMed=12079779; DOI=10.1016/S1074-5521(02)00163-1;
RA   Oguro A., Johnson L., Gershon P.D.;
RT   "Path of an RNA ligand around the surface of the vaccinia VP39 subunit
RT   of its cognate VP39-VP55 protein heterodimer.";
RL   Chem. Biol. 9:679-690(2002).
RN   [7]
RP   FUNCTION, AND MUTAGENESIS OF HIS-56; ILE-58; GLY-96 AND LYS-175.
RX   PubMed=12359447; DOI=10.1006/viro.2002.1538;
RA   Latner D.R., Thompson J.M., Gershon P.D., Storrs C., Condit R.C.;
RT   "The positive transcription elongation factor activity of the vaccinia
RT   virus J3 protein is independent from its (nucleoside-2'-O-)
RT   methyltransferase and poly(A) polymerase stimulatory functions.";
RL   Virology 301:64-80(2002).
RN   [8]
RP   ACTIVE SITE.
RX   PubMed=15134442; DOI=10.1021/bi0359980;
RA   Li C., Xia Y., Gao X., Gershon P.D.;
RT   "Mechanism of RNA 2'-O-methylation: evidence that the catalytic lysine
RT   acts to steer rather than deprotonate the target nucleophile.";
RL   Biochemistry 43:5680-5687(2004).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) IN COMPLEX WITH
RP   S-ADENOSYL-L-METHIONINE.
RX   PubMed=8612277; DOI=10.1016/S0092-8674(00)81101-0;
RA   Hodel A.E., Gershon P.D., Shi X., Quiocho F.A.;
RT   "The 1.85 A structure of vaccinia protein VP39: a bifunctional enzyme
RT   that participates in the modification of both mRNA ends.";
RL   Cell 85:247-256(1996).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) IN COMPLEX WITH SUBSTRATE
RP   ANALOGS.
RX   PubMed=9145102; DOI=10.1038/nsb0597-350;
RA   Hodel A.E., Gershon P.D., Shi X., Wang S.-M., Quiocho F.A.;
RT   "Specific protein recognition of an mRNA cap through its alkylated
RT   base.";
RL   Nat. Struct. Biol. 4:350-354(1997).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) IN COMPLEX WITH
RP   S-ADENOSYLHOMOCYSTEINE AND SUBSTRATE ANALOG.
RX   PubMed=9660928; DOI=10.1016/S1097-2765(00)80044-1;
RA   Hodel A.E., Gershon P.D., Quiocho F.A.;
RT   "Structural basis for sequence-nonspecific recognition of 5'-capped
RT   mRNA by a cap-modifying enzyme.";
RL   Mol. Cell 1:443-447(1998).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 1-307 IN COMPLEXES WITH
RP   SUBSTRATE ANALOGS.
RX   PubMed=10377383; DOI=10.1073/pnas.96.13.7149;
RA   Hu G., Gershon P.D., Hodel A.E., Quiocho F.A.;
RT   "mRNA cap recognition: dominant role of enhanced stacking interactions
RT   between methylated bases and protein aromatic side chains.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:7149-7154(1999).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.93 ANGSTROMS) OF 1-307 IN COMPLEX WITH
RP   SUBSTRATES.
RX   PubMed=12056899; DOI=10.1021/bi0201926;
RA   Hu G., Oguro A., Li C., Gershon P.D., Quiocho F.A.;
RT   "The 'cap-binding slot' of an mRNA cap-binding protein: quantitative
RT   effects of aromatic side chain choice in the double-stacking sandwich
RT   with cap.";
RL   Biochemistry 41:7677-7687(2002).
CC   -!- FUNCTION: Displays methyltransferase, positive regulation of the
CC       poly(A) polymerase and transcription elongation activities.
CC       Involved in the modification of both mRNA ends and in intermediate
CC       and late gene positive transcription elongation. At the mRNAs 5'
CC       end, methylates the ribose 2' OH group of the first transcribed
CC       nucleotide, thereby producing a 2'-O-methylpurine cap. At the 3'
CC       end, functions as a processivity factor which stimulates the
CC       activity of the viral poly(A) polymerase VP55 that creates mRNA's
CC       poly(A) tail. In the presence of VP39, VP55 does not dissociate
CC       from the RNA allowing tail elongation to around 250 adenylates.
CC       {ECO:0000269|PubMed:12359447, ECO:0000269|PubMed:1313572,
CC       ECO:0000269|PubMed:1670500}.
CC   -!- CATALYTIC ACTIVITY: S-adenosyl-L-methionine + a 5'-(N(7)-methyl
CC       5'-triphosphoguanosine)-(purine-ribonucleotide)-(mRNA) = S-
CC       adenosyl-L-homocysteine + a 5'-(N(7)-methyl 5'-
CC       triphosphoguanosine)-(2'-O-methyl-purine-ribonucleotide)-(mRNA).
CC   -!- SUBUNIT: Methyltransferase activity: Monomer, poly(A) polymerase
CC       activity: Heterodimer composed of a catalytic component, VP55, and
CC       a processivity factor, VP39. Interacts with Rap94 and NPH-I; these
CC       interactions might help linking transcription to capping and
CC       polyadenylation. {ECO:0000269|PubMed:11162828,
CC       ECO:0000269|PubMed:12056899, ECO:0000269|PubMed:1670500,
CC       ECO:0000269|PubMed:8612277, ECO:0000269|PubMed:9145102,
CC       ECO:0000269|PubMed:9660928}.
CC   -!- SUBCELLULAR LOCATION: Virion {ECO:0000305}. Note=Localizes to the
CC       virion core. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the class I-like SAM-binding
CC       methyltransferase superfamily. Poxvirus/kinetoplastid 2'-O-MTase
CC       family. {ECO:0000255|PROSITE-ProRule:PRU00944}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X01978; CAA26017.1; -; Genomic_DNA.
DR   EMBL; AY243312; AAO89374.1; -; Genomic_DNA.
DR   PIR; H23092; QQVZF9.
DR   RefSeq; YP_232977.1; NC_006998.1.
DR   PDB; 1AV6; X-ray; 2.80 A; A=3-297.
DR   PDB; 1B42; X-ray; 2.20 A; A=1-297.
DR   PDB; 1BKY; X-ray; 2.00 A; A=1-307.
DR   PDB; 1EAM; X-ray; 2.00 A; A=1-307.
DR   PDB; 1EQA; X-ray; 2.20 A; A=1-297.
DR   PDB; 1JSZ; X-ray; 1.93 A; A=1-307.
DR   PDB; 1JTE; X-ray; 2.00 A; A=1-307.
DR   PDB; 1JTF; X-ray; 2.60 A; A=1-307.
DR   PDB; 1P39; X-ray; 2.00 A; A=1-307.
DR   PDB; 1V39; X-ray; 1.80 A; A=1-307.
DR   PDB; 1VP3; X-ray; 1.90 A; A=1-333.
DR   PDB; 1VP9; X-ray; 1.95 A; A=1-307.
DR   PDB; 1VPT; X-ray; 1.80 A; A=1-333.
DR   PDB; 2GA9; X-ray; 2.30 A; A=1-297.
DR   PDB; 2GAF; X-ray; 2.40 A; A=1-297.
DR   PDB; 2VP3; X-ray; 1.95 A; A=1-307.
DR   PDB; 3ER8; X-ray; 3.18 A; A/B=1-297.
DR   PDB; 3ER9; X-ray; 2.06 A; A=1-297.
DR   PDB; 3ERC; X-ray; 3.21 A; A/B=1-297.
DR   PDB; 3MAG; X-ray; 1.80 A; A=1-307.
DR   PDB; 3MCT; X-ray; 2.00 A; A=1-297.
DR   PDB; 4DCG; X-ray; 1.80 A; A=1-307.
DR   PDBsum; 1AV6; -.
DR   PDBsum; 1B42; -.
DR   PDBsum; 1BKY; -.
DR   PDBsum; 1EAM; -.
DR   PDBsum; 1EQA; -.
DR   PDBsum; 1JSZ; -.
DR   PDBsum; 1JTE; -.
DR   PDBsum; 1JTF; -.
DR   PDBsum; 1P39; -.
DR   PDBsum; 1V39; -.
DR   PDBsum; 1VP3; -.
DR   PDBsum; 1VP9; -.
DR   PDBsum; 1VPT; -.
DR   PDBsum; 2GA9; -.
DR   PDBsum; 2GAF; -.
DR   PDBsum; 2VP3; -.
DR   PDBsum; 3ER8; -.
DR   PDBsum; 3ER9; -.
DR   PDBsum; 3ERC; -.
DR   PDBsum; 3MAG; -.
DR   PDBsum; 3MCT; -.
DR   PDBsum; 4DCG; -.
DR   ProteinModelPortal; P07617; -.
DR   SMR; P07617; 1-297.
DR   DIP; DIP-48310N; -.
DR   GeneID; 3707551; -.
DR   KEGG; vg:3707551; -.
DR   BRENDA; 2.1.1.57; 6591.
DR   EvolutionaryTrace; P07617; -.
DR   Proteomes; UP000000344; Genome.
DR   GO; GO:0019012; C:virion; IEA:UniProtKB-SubCell.
DR   GO; GO:0004483; F:mRNA (nucleoside-2'-O-)-methyltransferase activity; IEA:UniProtKB-EC.
DR   GO; GO:0003746; F:translation elongation factor activity; IEA:UniProtKB-KW.
DR   GO; GO:0006370; P:7-methylguanosine mRNA capping; IEA:UniProtKB-KW.
DR   GO; GO:0031440; P:regulation of mRNA 3'-end processing; IEA:InterPro.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   Gene3D; 3.40.50.150; -; 1.
DR   InterPro; IPR000176; mRNA_MeTrfase-like.
DR   InterPro; IPR025804; Pox/kineto_cap_MeTfrase.
DR   InterPro; IPR030375; Poxvir_cap_MeTfrase.
DR   InterPro; IPR029063; SAM-dependent_MTases.
DR   Pfam; PF01358; PARP_regulatory; 1.
DR   PIRSF; PIRSF003726; PolA_polym_reg_poxV; 1.
DR   SUPFAM; SSF53335; SSF53335; 1.
DR   PROSITE; PS51612; SAM_MT_2O_PK; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Direct protein sequencing;
KW   Elongation factor; Methyltransferase; mRNA capping; mRNA processing;
KW   Protein biosynthesis; Reference proteome; RNA-binding;
KW   S-adenosyl-L-methionine; Transcription; Transferase; Virion.
FT   CHAIN         1    333       Cap-specific mRNA (nucleoside-2'-O-)-
FT                                methyltransferase.
FT                                /FTId=PRO_0000099112.
FT   REGION      169    333       Binding to Rap94.
FT   REGION      169    249       Binding to NPH-I.
FT   REGION      177    180       mRNA cap binding.
FT   REGION      205    207       mRNA cap binding.
FT   ACT_SITE    175    175       For methyltransferase activity.
FT                                {ECO:0000305|PubMed:15134442}.
FT   BINDING      22     22       mRNA cap.
FT   BINDING      39     39       S-adenosyl-L-methionine.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00944,
FT                                ECO:0000269|PubMed:8612277}.
FT   BINDING      66     66       S-adenosyl-L-methionine.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00944,
FT                                ECO:0000269|PubMed:8612277}.
FT   BINDING      68     68       S-adenosyl-L-methionine; via carbonyl
FT                                oxygen. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00944,
FT                                ECO:0000269|PubMed:8612277}.
FT   BINDING      72     72       S-adenosyl-L-methionine; via amide
FT                                nitrogen. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00944,
FT                                ECO:0000269|PubMed:8612277}.
FT   BINDING      95     95       S-adenosyl-L-methionine.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00944,
FT                                ECO:0000269|PubMed:8612277}.
FT   BINDING      97     97       S-adenosyl-L-methionine.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00944,
FT                                ECO:0000269|PubMed:8612277}.
FT   BINDING     116    116       S-adenosyl-L-methionine; via amide
FT                                nitrogen and carbonyl oxygen.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00944,
FT                                ECO:0000269|PubMed:8612277}.
FT   BINDING     138    138       S-adenosyl-L-methionine.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00944,
FT                                ECO:0000269|PubMed:8612277}.
FT   BINDING     182    182       mRNA cap.
FT   BINDING     233    233       mRNA cap.
FT   MUTAGEN      56     56       H->R: Complete loss of poly(A) polymerase
FT                                stimulatory activity; when associated
FT                                with S-58. {ECO:0000269|PubMed:12359447}.
FT   MUTAGEN      58     58       I->S: Complete loss of poly(A) polymerase
FT                                stimulatory activity; when associated
FT                                with R-56. {ECO:0000269|PubMed:12359447}.
FT   MUTAGEN      96     96       G->D: Complete loss of elongation factor
FT                                activity. {ECO:0000269|PubMed:12359447}.
FT   MUTAGEN     175    175       K->R: Complete loss of methyltransferase
FT                                activity. {ECO:0000269|PubMed:12359447}.
FT   HELIX        13     15       {ECO:0000244|PDB:1V39}.
FT   HELIX        24     28       {ECO:0000244|PDB:1V39}.
FT   HELIX        37     55       {ECO:0000244|PDB:1V39}.
FT   TURN         58     61       {ECO:0000244|PDB:3ERC}.
FT   STRAND       63     68       {ECO:0000244|PDB:1V39}.
FT   HELIX        73     84       {ECO:0000244|PDB:1V39}.
FT   STRAND       90     97       {ECO:0000244|PDB:1V39}.
FT   HELIX       101    103       {ECO:0000244|PDB:1V39}.
FT   STRAND      109    113       {ECO:0000244|PDB:1V39}.
FT   HELIX       118    128       {ECO:0000244|PDB:1V39}.
FT   STRAND      133    137       {ECO:0000244|PDB:1V39}.
FT   HELIX       150    167       {ECO:0000244|PDB:1V39}.
FT   STRAND      170    176       {ECO:0000244|PDB:1V39}.
FT   HELIX       181    183       {ECO:0000244|PDB:1V39}.
FT   STRAND      188    191       {ECO:0000244|PDB:1V39}.
FT   STRAND      194    196       {ECO:0000244|PDB:1V39}.
FT   STRAND      208    213       {ECO:0000244|PDB:1V39}.
FT   STRAND      215    217       {ECO:0000244|PDB:1AV6}.
FT   STRAND      221    224       {ECO:0000244|PDB:1V39}.
FT   HELIX       226    241       {ECO:0000244|PDB:1V39}.
FT   HELIX       243    245       {ECO:0000244|PDB:1V39}.
FT   STRAND      246    248       {ECO:0000244|PDB:3ER8}.
FT   STRAND      253    255       {ECO:0000244|PDB:3ERC}.
FT   HELIX       258    267       {ECO:0000244|PDB:1V39}.
FT   HELIX       279    294       {ECO:0000244|PDB:1V39}.
SQ   SEQUENCE   333 AA;  38888 MW;  55A299DA4AAE1AD4 CRC64;
     MDVVSLDKPF MYFEEIDNEL DYEPESANEV AKKLPYQGQL KLLLGELFFL SKLQRHGILD
     GATVVYIGSA PGTHIRYLRD HFYNLGVIIK WMLIDGRHHD PILNGLRDVT LVTRFVDEEY
     LRSIKKQLHP SKIILISDVR SKRGGNEPST ADLLSNYALQ NVMISILNPV ASSLKWRCPF
     PDQWIKDFYI PHGNKMLQPF APSYSAEMRL LSIYTGENMR LTRVTKSDAV NYEKKMYYLN
     KIVRNKVVVN FDYPNQEYDY FHMYFMLRTV YCNKTFPTTK AKVLFLQQSI FRFLNIPTTS
     TEKVSHEPIQ RKISSKNSMS KNRNSKRSVR SNK
//
